Classification of cardiac arrhythmias based on alphabet entropy of heart rate variability time series

2017 ◽  
Vol 31 ◽  
pp. 217-230 ◽  
Author(s):  
Alan Jovic ◽  
Franjo Jovic
1995 ◽  
Vol 269 (2) ◽  
pp. H480-H486 ◽  
Author(s):  
Y. Yamamoto ◽  
J. O. Fortrat ◽  
R. L. Hughson

The purpose of the present study was to investigate the basic fractal nature of the variability in resting heart rate (HRV), relative to that in breathing frequency (BFV) and tidal volume (TVV), and to test the hypothesis that fractal HRV is due to the fractal BFV and/or TVV in humans. In addition, the possible fractal nature of respiratory volume curves (RVC) and HRV was observed. In the first study, eight subjects were tested while they sat quietly in a comfortable chair for 60 min. Beat-to-beat R-R intervals, i.e., HRV, and breath-by-breath BFV and TVV were measured. In the second study, six subjects were tested while they were in the supine position for 20-30 min. The RVC was monitored continuously together with HRV. Coarse-graining spectral analysis (Yamamoto, Y., and R. L. Hughson, Physica D 68: 250-264, 1993) was applied to these signals to evaluate the percentage of random fractal components in the time series (%Fractal) and the spectral exponent (beta), which characterizes irregularity of the signals. The estimates of beta were determined for each variable only over the range normally used to evaluate HRV. Values for %Fractal and beta of both BFV and TVV were significantly (P < 0.05) greater than those for HRV. In addition, there was no significant (P > 0.05) correlation between the beta values of HRV relative to either BFV (r = 0.14) or TVV (r = 0.34). RVC showed a smooth oscillation as compared with HRV; %Fractal for RVC (42.3 +/- 21.7%, mean +/- SD) was significantly (P < 0.05) lower than that for HRV (78.5 +/- 4.2%).(ABSTRACT TRUNCATED AT 250 WORDS)


2013 ◽  
Vol 111 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Miguel A. García-González ◽  
Mireya Fernández-Chimeno ◽  
Lluis Capdevila ◽  
Eva Parrado ◽  
Juan Ramos-Castro

2016 ◽  
pp. 67-74
Author(s):  
Maryna Dolzhenko ◽  
Olena Popovich ◽  
Oksana Shershnyova ◽  
Oleksandr Nudchenko ◽  
Kardo Faradzh ◽  
...  

The objective: to evaluate the efficiency of ethylmethylhydroxypyridine (Mexiprim, STADA Arzneimittel AG, Germany) in patients presenting with myocardial infarction at hospital and outpatient stage. Patients and methods. The study included 59 patients with coronary artery disease, acute coronary syndrome with ST1segment elevation in the first day of admission to the ICU, AH, 3-stage, 2 degrees, HF. To all patients basic therapy according to current ESH/ESC guidelines was prescribed. To 39 patients additionally intravenous infusion of 200 mg of mexiprim o.d. for 10 days, followed by 125 mg per os three times a day for next 60 days was administered. Another 20 patients presented control group and received only basic therapy. The study design included: 24-hour Holter monitoring to estimate the dynamics of changes in the ST segment, cardiac arrhythmias and heart rate variability, evaluation by the scale of Beck, Hamilton scale for the assessment of anxiety (HARS) and depression (HDRS), the common blood and urine tests, biochemical blood analysis, evaluation of therapeutic tolerability conducted before treatment and 60 days after treatment. Surveys on a scale SAN, assessment of cognitive impairment on the MMSE scale were performed on the 60th day of treatment. Efficiency criteria were: a 50% reduction of cardiac arrhythmias, a decrease in ischemia, a decrease by 50% or more from baseline average score by HARS, HDRS scales, dynamics of the mental state questionnaire and less than 9 points on a scale of depression, reducing in SAN scale score. Results. In pаtients of mexiprim group significant reduction of depression scores by 62% were observed. According to the dynamics of the mental state questionnaire patients of mexiprim group reported feeling better, that is, reduction of score by 45% . According to the Hamilton scale for the assessment of anxiety (HARS), in particular mental anxiety – decrease in the total score of 65%, somatic anxiety – by 35.5%, and a total of 50% were revealed. In the group of patients receiving additionally intravenous Mexiprim for 10 days significantly reduced the number of single and group PACs, as well as single and multiple PVCs, not only in comparison with these parameters before the treatment, but also in comparison with the control group. In patients treated with Mexiprim no evidence of residual ischaemia were noted, but in the control group statistically significant segment depression ST remained. Heart rate variability was not significantly changed in the control group, but increased in patients who received Mexiprim. Conclusion. Use of Mexiprim in patients with myocardial infarction reduces ST segment depression, amount of ventricular and supraventricular arrhythmias, improved heart rate variability, and the state of anxiety and depression.


Author(s):  
Anna Persson ◽  
Hanna Jonasson ◽  
Ingemar Fredriksson ◽  
Urban Wiklund ◽  
Christer Ahlstrom

Sign in / Sign up

Export Citation Format

Share Document